Infection with the Omicron variant of the SARS-CoV-2 virus is associated with a common respiratory illness in young children, known as croup, a previously unrecognised complication of COVID-19, according to a study.
The observational study, published recently in the journal Pediatrics, describes 75 children who came to the Boston Children's Hospital emergency department (ED) with croup and COVID-19 from March 1, 2020 to January 15, 2022.
The researchers noted that some cases were surprisingly severe, requiring hospitalisation and more medication doses compared to croup caused by other viruses, adding that just over 80 per cent occurred during the Omicron period.
"There was a very clear delineation from when Omicron became the dominant variant to when we started seeing a rise in the number of croup patients," said study first author Ryan Brewster, from Boston Children's Hospital and Boston Medical Center.
Croup, also known as laryngotracheitis, is a common respiratory illness in babies and young children.
The illness is marked by a distinctive barking cough and sometimes noisy, high-pitched intakes of breath known as stridor.
It happens when colds and other viral infections cause inflammation and swelling around the voice box, windpipe, and bronchial tubes.
In severe cases, including some seen at Boston Children's, croup can dangerously constrict breathing, the researchers said
Previous studies of COVID-19 in animals have found that the Omicron variant has more of a "preference" for the upper airway than earlier variants, which mainly targeted the lower respiratory tract.
This may account for the sudden appearance of croup during the Omicron surge, Brewster said.
Most of the children with COVID-19 and croup were under age 2, and 72 per cent were boys. Except for one child with a common cold virus, all others were infected with SARS-CoV-2.
Although no children died, nine of the 75 children with COVID-19-associated croup (12 per cent) needed to be hospitalised and four of them (44 per cent, or 5 per cent of the total) required intensive care, the researchers said.
By comparison, before COVID-19, fewer than 5 per cent of children with croup were hospitalised, and of those, only 1 to 3 per cent required intubation, they said.
Overall, 97 per cent of the children were treated with dexamethasone, a steroid.
All of those who were hospitalised received treatment which is reserved for moderate or severe cases, as did 29 per cent of children treated in the ED.
"Most cases of croup can be managed in the outpatient setting with dexamethasone and supportive care," said Brewster.
"The relatively high hospitalisation rate and the large number of medication doses our COVID-19 croup patients required suggests that COVID-19 might cause more severe croup compared to other viruses," he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)